Biomedical subjects
G Bendixen
Publications and source records attributed to G Bendixen.
Human leucocyte response to migration inhibitory activity from lymphocytes. Modification by aprotinin, Tranexamic acid and phenylmethyl sulfonylfluoride.
Human lymphokines can elicit several effects associated with inflammation, e.g. leucocyte migration inhibition and fibrinolysis. These effects can be assessed in vitro by the leucocyte migration agarose technique (LMAT) and the leucocyte migration fibrinolysis technique (LMFT). The present study shows that preincubation of normal leucocytes with aprotinin, tranexamic acid and phenyl-methyl-sulfonylfluoride (PMSF) reduces or abolishes their migration inhibition response to leucocyte migration inhibition factor. The compounds exert this effect at non-toxic concentrations, which do not otherwise interfere with migration or fibrinolysis, and are non-toxic as estimated by PHA stimulation of lymphocytes. The LMFT is more sensitive to the modifying effect than the LMAT. The effect of aprotinin and tranexamic acid is reversible, the effect of PMSF is irreversible.
Humoral and cellular immunity in sarcoidosis.
The Kveim reaction was studied in vivo in 50 patients with sarcoidosis. Commonwealth Serum Laboratories Kveim material and a new Danish Kveim material gave 14 and 8 positive reactions respectively, as well as 6 and 8 equivocal reactions. Forty-six of the patients were also tested in vitro for cell mediated immunity to the Danish Kveim material, using both the leucocyte migration agarose technique and the capillary technique. No significant migration inhibition or stimulation were found. A tuberculin skin test was performed in 49 of the patients, and in 45 a dinitrochlorobenzene sensitivity titer was determined. Both tests revealed a depression of the cell mediated immunity. The serum levels of immunoglobulins IgG, IgA, IgM, IgD, and IgE were determined. The serum of each patient was also examined to determine if organ-non-specific and granulocyte-specific antinuclear factors of IgG class, antibodies against native DNA, rheumatoid factor, mitochondrial antibodies, antibodies against thyroid cytoplasm, and parietal cell antibodies were present. IgG levels were above normal in 28 patients; IgE was above normal in 10 patients, 4 of whom were atopics or had an atopic disposition. Organ-non-specific antinuclear factors were present in 17 patients.
Anti-DNA antibody in serum measured by radioimmunoassay (Farr technique). Description of method and recommended procedure.
Anti-DNA antibody determination in serum is increasingly used because it supports the diagnosis of systemic lupus erythematosus (SLE) with high selectivity. The present work evaluates several of the technical variables of the Farr radioimmunoassay for anti-DNA antibody determination and describes a recommendable procedure, emphasizes the most important sources of error and gives the range of normal blood donors and a group of hospital patients without SLE.
Cell-mediated immunity of Yersinia enterocolitica serotype 3 in patients with thyroid diseases.
The cellular immunity to Yersinia enterocolitica serotype 3 and crude human thyroid extract in 64 patients with thyroid diseases and 25 controls was studied by the leucocyte migration test. In the patient group as a whole and in patients with Graves' disease and nontoxic diffuse goitre a significantly reduced leucocyte migration towards Yersinia was found when compared with the controls. In controls the migration index was not related to the presence or titre of circulating yersinia antibodies, whereas the migration index of patients with yersinia antibodies was lower than the migration index of patients without yersinia antibodies as well as that of the controls. The leucocyte migration inhibition in two patients with recent yersinosis was normal during the recovery phase. In the presence of thyroid extract leucocyte migration inhibition differed only significantly in Graves' disease. However, a significantly positive correlation between inhibition of migration by thyroid extract and by Yersinia was found, while no correlation could be demonstrated in the controls. The cell-mediated immunity towards Yersinia in thyroid diseases thus demonstrated adds further evidence to the association between Yersinia and thyroid disease.
Pathogenic importance of lymphocyte products.
Explore the source record for details and available documents.
In vitro diagnosis of reagin-mediated allergy.
Explore the source record for details and available documents.
Anti-DNA antibody determination in systemic lupus erythematosus (SLE). Predictive value as compared with the LE-cell test.
All pathological LE-cell tests and anti-DNA antibody determinations were registered in a prospective study over a period of 9 months at a department of internal medicine with rheumatology as a subspecialty. The results were compared with the clinical diagnosis of the patients, and correlated to SLE disease activity, as evaluated clinically and by blood analysis of five acute-phase reactants. Of 159 positive LE-cell tests, 43 were from patients with SLE, giving a diagnostic value of 27%. Of 37 positive anti-DNA antibody values, 30 were from patients having SLE, giving a diagnostic value of 81%. All of the 7 false-positive anti-DNA antibody determinations were only slightly above the normal range (22--26%: normal range less than or equal to 21%). No correlation was found between the activity of the SLE and the degree of the positive LE-cell test. Pathological levels of anti-DNA antibodies were always found when the patient had active SLE--clinically and by elevation of acute phase reactants. On the other hand, it was impossible to evaluate the disease activity from the level of the anti-DNA antibody test. It is concluded that the anti-DNA antibody determination should be preferred to the LE-cell test in the evaluation of patients with connective tissue diseases.
Thyroid disease and Yersinia.
Explore the source record for details and available documents.
Leucocyte migration inhibitory activity of concanavalin-A-stimulated lymphocytes. In vivo and in vitro modifications with dipyridamole and acetylsalicylic acid.
Lymphocytes from 14 patients treated with a combination of acetylsalicylic acid (ASA) and dipyridamole (DIPY) showed a decreased ability to produce leucocyte migration inhibitory activity (LMIA) when stimulated with concanavalin-A (ConA). The combined treatment also produced a decrease of leucocyte response to a standard LMIA-containing culture supernatant. Treatment with only one of the two drugs did not cause detectable alteration of the lymphocyte response to Con-A or the leucocyte response to LMIA. In vitro, both DIPY and ASA were independently effective in decreasing the LMIA production of Con-A-stimulated lymphocytes and the leucocyte response to a standard LMIA-containing culture supernatant.
Leucocyte migration fibrinolysis technique (LMFT): description of a method.
Human leucocytes can migrate in a gel medium consisting of fibrin, 10% horse serum and tissue culture medium 199. The cells migrate within the fibrin gel mass. The 24 h. areas of migration depend upon the volume and concentration of the cell suspension applied on the fibrin gel. The amount of cells per mm2 migration culture area is less than half the amount used in the leucocyte migration agarose test. The results are reproducible, the standard variation of the migration areas is below 10%. The method is potentially useful for several purposes such as for measuring fibrinolytic and migratory activity of granulocytes, monocytes and lymphocytes and modification of these functions by lymphokines.
Diagnostic limits of collagen diseases.
Explore the source record for details and available documents.
[International Conference on Immunotherapy of Cancer. New York, 5.-7.XI.1975].
Explore the source record for details and available documents.
Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin.
The in vitro effects of heparin, dipyridamole (DIPY) and lysine-acetylsalicylate (LASA) on human peripheral blood leucocyte migration and upon production/release and effect of leucocyte migration inhibitory activity (LMIA) from lymphocytes stimulated with concanavalin-A (con-A) have been studied. The final concentration of each drug was of the same order of magnitude as during clinical treatment. The leucocyte migration under agarose was significantly increased by DIPY at a concentration of 100 mug/ml. The release/production of LMIA was inhibited by DIPY at 1 mug/ml and by LASA at 0.3 mug/ml. Heparin had no influence on LMIA release, even at 10 IU/ml. The LMIA of supernatants from con-A-stimulated lymphocyte cultures was inhibited by DIPY at a concentration of 10 mug/ml, by LASA at 3 mug/ml and by heparin at 10 IU/ml. The findings suggest that DIPY and LASA could have a dual role as modifiers of inflammation: 1) the well known role as antiaggregants tending to limit and impede thrombosis, and 2) as antagonists to the lymphocyte-mediated (type IV) immune reaction through a depressive action on lymphokine production/release and activity.
Human leucocyte migration inhibition.
Within the last decade a variety of techniques have been developed and used for the detection of cell-mediated immunity in man by means of leucocyte migration inhibition in vitro. A detailed description of the leucocyte migration capillary tube technique (LMCT) and the leucocyte migration agarose technique (LMAT) is given. The procedure for selecting and using the proper antigen concentration is described. A description is also given of the indirect LMAT and the technique for determination of concanavalin A-induced lymphocyte release of leucocyte migration inhibition factor. Applications of these techniques are mainly intended for the exploration of the immunobiology of lymphocytes and cellular interactions associated with the immune response and the investigation of clinical conditions in man, i.e. infectious diseases, autoimmune diseases, transplantation states, tumour diseases, contact hypersensitivity and immunological deficiency states. Selection and adaptation to suit the experimental aim is necessary to obtain optimal results with these techniques. Their usefulness may be increased through more extensive use of purified antigens and indirect assays.
Lymphokines and thrombosis. II. Procoagulant activity produced by human lymphocytes stimulated with concanavalin A (con-A).
Human lymphocytes stimulated with concanavalin-A produce a coagulant activity which decreases the clotting time as expressed through the recalcification time of citrated plasma, the partial thromboplastin time, the thrombin clotting time of citrated plasma and the thrombin clotting time of fibrinogen solutions. The culture supernatants of human lymphocytes stimulated with concanavalin-A also have a direct coagulant effect on human fibrinogen solution. They decrease the lag period of recalcification time of citrated plasma but do not modify the duration of polymerization as measured with a spectrophotometric method.
Discussion paper: tumor-directed cellular hypersensitivity detected by leucocyte migration in patients with renal carcinoma.
Leucocyte migration inhibition detected in vitro by the capillary tube technique (LMCT) has proved a useful tool for detection of tumor-specific cell-mediated hypersensitivity (TCMH) in man. Investigations in pateints with renal tumors are reported. It is shown that TCMH is a feature of hypernephroma in man, that the antigenic specificity is found in autologous as well as allogeneic tumor tissue and in fetal kidney tissue. The pattern of reactivity compared to postoperative survival and occurrence of metastases and postoperative clinical course shows a clear association between TCMH and tumor elimination. The capacity of hypernephroma patients to develop a cell-mediated immune response is generally not reduced. In allogeneic combinations, small noninvading tumors usually have a high antigenicity, whereas tumors with early dispersion show a low antigenicity. The development of TCMH and associated tumor elimination therefore may be depending preferably on the antigenicity of the tumor, less on the immune capacity of the tumor host.